Israeli - Kiingereza - Ministry of Health

glaxo smith kline (israel) ltd - clobetasol 17- propionate - cream - clobetasol 17- propionate 0.05 %w/w - clobetasol - clobetasol - clobetasol is a very potent topical corticosteroid indicated for adults, elderly and children over 1 year for the short term treatment only of more resistant inflammatory and pruritic manifestations of steroid responsive dermatoses unresponsive to less potent corticosteroids. these include the following:• psoriasis (excluding widespread plaque psoriasis)• recalcitrant dermatoses • lichen planus• discoid lupus erythematosus • other skin conditions which do not respond satisfactorily to less potent steroids.

Marekani - Kiingereza - NLM (National Library of Medicine)

novel laboratories, inc. - clobetasol propionate (unii: 779619577m) (clobetasol - unii:adn79d536h) - clobetasol propionate ointment usp is a super-high potency corticosteroid formulation indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. treatment beyond 2 consecutive weeks is not recommended, and the total dosage should not exceed 50 g/week because of the potential for the drug to suppress the hypothalamic-pituitary-adrenal (hpa) axis. use in pediatric patients under 12 years of age is not recommended. as with other highly active corticosteroids, therapy should be discontinued when control has been achieved. if no improvement is seen within 2 weeks, reassessment of the diagnosis may be necessary. clobetasol propionate ointment, 0.05% is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparations.

Marekani - Kiingereza - NLM (National Library of Medicine)

lupin pharmaceuticals,inc. - clobetasol propionate (unii: 779619577m) (clobetasol - unii:adn79d536h) - clobetasol propionate ointment usp is a super-high potency corticosteroid formulation indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. treatment beyond 2 consecutive weeks is not recommended, and the total dosage should not exceed 50 g/week because of the potential for the drug to suppress the hypothalamic-pituitary-adrenal (hpa) axis. use in pediatric patients under 12 years of age is not recommended. as with other highly active corticosteroids, therapy should be discontinued when control has been achieved. if no improvement is seen within 2 weeks, reassessment of the diagnosis may be necessary. clobetasol propionate ointment, 0.05% is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparations.

Ujerumani - Kijerumani - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

acis arzneimittel gmbh (8087957) - clobetasolpropionat (ph.eur.) - lösung zur anwendung auf der haut - teil 1 - lösung zur anwendung auf der haut; clobetasolpropionat (ph.eur.) (11901) 0,5 milligramm

Ujerumani - Kijerumani - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

acis arzneimittel gmbh (8087957) - clobetasolpropionat (ph.eur.) - creme - teil 1 - creme; clobetasolpropionat (ph.eur.) (11901) 0,5 milligramm

Ujerumani - Kijerumani - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

acis arzneimittel gmbh (8087957) - clobetasolpropionat (ph.eur.) - salbe - teil 1 - salbe; clobetasolpropionat (ph.eur.) (11901) 0,5 milligramm

Ujerumani - Kijerumani - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

acis arzneimittel gmbh (8087957) - clobetasolpropionat (ph.eur.) - salbe - teil 1 - salbe; clobetasolpropionat (ph.eur.) (11901) 0,5 milligramm

Ureno - Kireno - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

ratiopharm - comércio e indústria de produtos farmacêuticos, lda. - clobetasol - creme - 0.5 mg/g - clobetasol, propionato 0.5 mg/g - clobetasol - genérico - duração do tratamento: curta ou média duração

Chile - Kihispania - ISPC (Instituto de Salud Pública de Chile)

b y b farmacÉutica ltda. - clobetasol - clobetasol propionato 0,05 g contenido - clobetasol propionato crema está indicado en el tratamiento a corto plazo de manifestaciones inflamatorias y pruríticas de dermatosis que no responden a corticoides menos activos.

Ujerumani - Kijerumani - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

smartpractice europe gmbh (8106407) - clobetasolpropionat (ph.eur.) - salbe - teil 1 - salbe; clobetasolpropionat (ph.eur.) (11901) 2,12 milligramm